| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.5 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |